This inventor holds 1 USPTO granted patent. Top assignee: Glaxosmithkline Biologicals Sa. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Janina Gergen: Innovator in Nucleic Acid Vaccines
Introduction
Janina Gergen is a prominent inventor based in Tübingen, Germany. She has made significant contributions to the field of biotechnology, particularly in the development of vaccines against emerging viral threats. Her work is crucial in the ongoing fight against infectious diseases.
Latest Patents
Janina Gergen holds a patent for a "Nucleic acid base vaccine against emerging SARS-CoV-2 variants." This invention is directed to nucleic acids suitable for use in the treatment or prophylaxis of infections caused by coronaviruses, such as SARS-CoV-2 variants. The patent also encompasses compositions and vaccines that include nucleic acid sequences in association with lipid nanoparticles (LNP). Furthermore, it outlines methods for treating or preventing coronavirus infections, including those related to COVID-19.
Career Highlights
Throughout her career, Janina has focused on innovative solutions to combat viral infections. Her work has been instrumental in advancing vaccine technology, particularly in response to the COVID-19 pandemic. She is recognized for her expertise and dedication to public health.
Collaborations
Janina collaborates with notable colleagues, including Hans Wolfgang Große and Kristina Kovacikova. These partnerships enhance her research and contribute to the development of effective medical solutions.
Conclusion
Janina Gergen's contributions to vaccine development highlight her role as a key innovator in the biotechnology field. Her work on nucleic acid vaccines is vital for addressing current and future viral threats.